1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Guangdong VTR Bio-Tech Co., Ltd.

Guangdong VTR Bio-Tech Co., Ltd.

300381.SZ
Guangdong VTR Bio-Tech Co., Ltd.CN flagShenzhen Stock Exchange
5.70
CNY
-0.09
- -
2.74BMarket Cap
Guangdong VTR Bio-Tech Co., Ltd.
300381.SZ
(Shenzhen Stock Exchange)

Recent

price

5.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.93
1.16
1.44
1.54
1.32
2.29
3.94
3.69
4.35
4.91
4.11
3.86
2.4
1.62
1.68
1.7
1.72
Revenue per Share
0.12
0.18
0.23
0.27
0.2
0.23
0.3
0.2
0.28
0.31
0.35
-0.24
0.04
-0.02
0.06
-0.04
0.01
Basic EPS, GAAP
0.13
0.16
0.11
0.04
-0.13
-0.14
-1
-0.87
-0.26
0.11
0.26
0.11
0.11
-0.49
-0.63
-0.32
-0.59
Free Cash Flow per Basic Share
0.02
0.01
- -
- -
0.08
0.1
0.14
0.17
0.25
0.17
0.14
0.14
0.13
0.1
0.07
0.1
0.01
Dividend per Share
0.54
0.71
0.92
1.17
1.33
1.4
2.12
2.14
2.38
2.63
2.73
2.28
2.14
2.02
2.03
1.89
1.95
Book Value per Share
0.57
0.76
0.99
1.27
1.89
2.48
3.51
3.13
3.86
4.52
5.16
4.55
5.14
4.84
4.69
4.53
4.59
Tangible Book Value per Share
234
234
234
234
272
307
384
407
407
418
466
490
490
491
490
491
492
Basic Weighted Avg Shares
217
270
337
359
360
703
1,512
1,499
1,768
2,048
1,915
1,892
1,174
796
826
832
844
Sales/Revenue/Turnover
16.67
18.03
18.73
19.37
17.39
13.46
12.8
15.21
15.52
13.44
16.56
6.72
-4.97
-2.72
2.02
0.01
1.1
Operating Margin (%)
11
10
10
10
14
38
92
106
124
153
155
168
138
112
113
129
- -
Depreciation Expense
28
43
55
63
55
72
114
80
114
128
162
-119
18
-11
31
-20
3
Net Income, GAAP
16.16
13.47
14.41
14.4
13.4
14.6
8.4
15.6
15.77
11.16
12.78
- -
64.29
9.92
- -
- -
70.13
Effective Tax Rate (%)
13
15.96
16.22
17.58
15.32
10.21
7.51
5.36
6.42
6.23
8.45
-6.28
1.55
-1.35
3.76
-2.38
0.39
Profit Margin (%)
52
97
133
142
315
177
547
331
1,144
927
938
785
1,794
1,386
1,041
829
1,000
Working Capital
- -
- -
- -
- -
90
160
206
146
727
486
119
127
51
- -
- -
- -
- -
LT Debt
145
188
243
306
685
1,416
2,055
2,090
2,407
2,729
3,263
3,048
2,816
2,735
2,654
2,593
2,631
Total Equity
18.35
21.76
23.7
21.69
10.01
5.85
7.45
6.49
6.26
6.13
7.14
- -
-0.62
-0.68
- -
- -
- -
Return on Invested Capital (%)
19.56
25.64
26.92
25.8
13.88
8.82
8.42
5.29
5.61
5.28
6.83
- -
0.34
-1.58
- -
- -
1.13
Return on Capital (%)
24.16
29.4
28.66
25.82
17.35
18.14
18.25
9.55
12.35
12.35
13.66
-9.96
1.68
-1.05
3.13
-2.06
0.34
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
35
35
82
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
491
491
491
Market Capitalization
3,437
3,719
3,700

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,283
1,232
1,221
Cash, Cash Equivalents & STI
799
728
706
Accounts Receivable, Net
208
220
220
Inventories
195
200
204
Total Current Liabilities
243
179
221
Payables & Accruals
- -
- -
- -
ST Debt
35
35
82
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.26%
-4.47%
-2.3%
Free Cash Flow
9.82%
-128.18%
-49.33%
Net Income, GAAP
-89.14%
-200.13%
-163.62%
Sales/Revenue/Turnover
7.46%
-13.36%
0.73%
Total Cash Common Dividend
9.34%
-1.89%
42.09%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
199
198
211
218
826
2025
202
213
219
- -
832
2026
213
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
- -
- -
- -
0.06
2025
0.01
- -
- -
- -
-0.04
2026
0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.07
2025
- -
- -
- -
- -
0.1
2026
- -
- -
- -
- -
- -
Similar Companies
Windtree Therapeutics, Inc. (WINTW)
Laekna, Inc. (2105.HK)
ImmunoPrecise Antibodies Ltd. (IPA)
Cassava Sciences, Inc. (SAVA)
CombiMatrix Corporation (CBMX)
Pasithea Therapeutics Corp. (KTTA)
Business
Guangdong VTR Bio-Tech Co., Ltd. is a biotechnology company primarily engaged in the research, development, production, sales, and service of biological enzyme preparations, biosynthetic products, and plant extracts. Its main products include feed enzymes (such as phytase, protease, xylanase, and Macleaya cordata extract), energy enzymes, washing enzymes, food enzymes, papermaking enzymes, textile enzymes, and various active natural products. The company also produces veterinary active pharmaceutical ingredients and formulations, along with botanical extracts like rosemary, echinacea, and verbena. Founded in 1991 and headquartered in Zhuhai, Guangdong Province, China, VTR Bio-Tech operates across multiple industries including agriculture and animal husbandry, biomanufacturing, and biomedical sectors with a significant presence both domestically and internationally. Recently, VTR Bio-Tech has undertaken several major initiatives reflecting its strategic focus on innovation and sustainable growth. The company opened a new R&D office building in Changsha in 2025, expanded its intelligent factory and National Enterprise Technology Center in Zhuhai, and held a major new product launch event in 2024 unveiling Yiduozyme, a next-generation xylanase, and the Yibeijia Com Series, a versatile detergent enzyme solution. VTR Bio-Tech has also accelerated its internationalization strategy, showcasing cutting-edge animal feed enzyme solutions at industry events such as VIV Asia 2025 and forming strategic partnerships to enhance its global market presence. These developments underline its commitment to advancing sustainable biotechnology and delivering efficient, high-performance bio-solutions to global customers. VTR Bio-Tech serves a diversified customer base in sectors including animal feed, agriculture, industrial biotechnology, and pharmaceutical research, targeting markets in China, Southeast Asia, and beyond. The company’s comprehensive biotechnology solutions focus on improving feed efficiency, reducing production costs, and promoting greener production processes. Its strategic emphasis remains on innovation-driven growth and expanding its product portfolio to meet evolving market demands worldwide.